Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who had had a recent acute coronary syndrome. METHODS: We randomly assigned patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 to 90 days to receive alogliptin or placebo in addition to existing antihyperglycemic and cardiovascular drug therapy. The study design was a double-blind, noninferiority trial with a prespecified noninferiority margin of 1.3 for the hazard ratio for the primary end point of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 5380 patients underwent randomization and were followed for up to 40 months (median, 18 months). A primary end-point event occurred in 305 patients assigned to alogliptin (11.3%) and in 316 patients assigned to placebo (11.8%) (hazard ratio, 0.96; upper boundary of the one-sided repeated confidence interval, 1.16; P<0.001 for noninferiority). Glycated hemoglobin levels were significantly lower with alogliptin than with placebo (mean difference, -0.36 percentage points; P<0.001). Incidences of hypoglycemia, cancer, pancreatitis, and initiation of dialysis were similar with alogliptin and placebo. CONCLUSIONS: Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DPP-4 inhibitors do not have significant GI adverse effects and may be used in early combination with metformin.1038–1043”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1038]
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [20]
In the citing paper
“Pharmaceutical interventions of 1.5 to 3 years duration report HbA1c reductions of 0.2 to 1.0% with DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists (6, 7, 49).”
In the citing paper
“GLP-1 agents, including dipeptidyl peptidase-4 (DPP-4) inhibitor and glucagon-like peptide-1 receptor agonist (GLP-1 Ra), enhance insulin secretion in pancreatic b-cell and showed many benefits in treating diabetes mellitus type 2 but are not a common choice for GDM [117,118].”
From Gestational Diabetes Mellitus—Recent Literature Review (2022) · cites this paper as [117]
In the citing paper
“Evidence that glucose lowering reduces the rates of cardiovascular events and death has not been convincingly shown, 4-6”
From Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015) · cites this paper as [5]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Self-citationUniversal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Task Force Members, Thygesen, K., Alpert, J. S., White, H. D., Biomarker Group, Jaffe, A. S., Apple, F. S., Galvani, M., Katus, H. A., Newby, L. K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm355 · Cited by 2,541
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Cited by
Items 901–1,000 of 1,012
The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements
Toumi, M., Jarosławski, S., Sawada, T., & Kornfeld, A. (2016) · Applied Health Economics and Health Policy · doi:10.1007/s40258-016-0274-x · Cited by 25
“However, faced with non-favourable HTA recommendations and growing competition from similar treatments, some of the manufacturers invested in longterm cardiovascular studies showing that it was feasible [47, 48].”
BackgroundThe Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer
Amin, S., Boffetta, P., & Lucas, A. L. (2016) · Gut and Liver · doi:10.5009/gnl15451 · Cited by 25
Renal outcomes with dipeptidyl peptidase-4 inhibitors
Scheen, A. J., & Delanaye, P. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.07.011 · Cited by 29
Doğruel, H., & Balcı, M. K. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i8.446 · Cited by 28
Ueki, K., Tanizawa, Y., Nakamura, J., Yamada, Y., Inagaki, N., Watada, H., Shimomura, I., Nishimura, R., Miyoshi, H., Abiko, A., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001787 · Cited by 27
“8 13 It is thus important to examine DPP-4 inhibitors for a longer period in the subjects who are not at high cardiovascular risk to entirely clarify the safety issues suggested and unidentified for the drug class.”
Bae, J. H., Park, E.-G., Kim, S., Kim, S. G., Hahn, S., & Kim, N. H. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.912 · Cited by 31
“Random sequence generation and allocation concealment were not reported in two studies [28,34].”
BackgroundMethodExenatide Activates the APPL1-AMPK-PPARαAxis to Prevent Diabetic Cardiomyocyte Apoptosis
XiaoTian, L., Wu, Q., XiaGuang, G., WuQuan, D., Chen, B., & ZiWen, L. (2015) · Journal of Diabetes Research · doi:10.1155/2016/4219735 · Cited by 27
Gong, Q., Rajagopalan, S., & Zhong, J. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.06.076 · Cited by 32
“However, recently completed large-scale phase 3 and phase 4 clinical trials (EXAMINE and SAVOR-TIMI 53) showed no significant improvements in primary cardiovascular endpoints in patients treated with DPP4 enzymatic inhibitors compared to those with placebo [7,8], calling into question the cardiovascular efficacy of th…”
BackgroundThe Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure
Scirica, B. M. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.0184 · Cited by 26
Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease: A Clinical Conundrum
Aguilar, D. A. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003316 · Cited by 25
“Studies also required treatment dose reductions based on renal function.(10,13,14) The outcomes of these studies have also provided important data.”
BackgroundResultSchnell, O., Standl, E., Catrinoiu, D., Genovese, S., Lalic, N. M., Lalic, K. S., Škrha, J., Valensi, P. E., & Ceriello, A. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0667-2 · Cited by 28
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors
Tomkin, G. H. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.636 · Cited by 24
Poledniczek, M., Neumayer, C., Kopp, C. W., Schlager, O., Gremmel, T., Józkowicz, A., Gschwandtner, M. E., Koppensteiner, R., & Wadowski, P. P. (2023) · Biomedicines · doi:10.3390/biomedicines11082284 · Cited by 29
Geiger, M. J., Mehta, C. R., Turner, J. R., Arbet‐Engels, C., Hantel, S., Hirshberg, B., Koglin, J., Mendzelevski, B., Sager, P. T., Shapiro, D., et al. (2015) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479014549860 · Cited by 25
Self-citationNagamine, A., Hasegawa, H., Hashimoto, N., Yamada-Inagawa, T., Hirose, M., Kobara, Y., Tadokoro, H., Kobayashi, Y., & Takano, H. (2017) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.12.003 · Cited by 24
Chen, X., He, Z., Zhou, Z., Yang, T., Zhang, X., Yang, Y., Duan, W., & Zhou, S. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12469 · Cited by 24
“The long-term CV safety of alogliptin was evaluated in a recent randomized, placebo-controlled, noninferiority trial, Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE), involving 5380 patients with T2DM and a recent acute coronary syndrome (ACS).(93) EXAMINE concludes that among…”
BackgroundBrenner, C., Adrion, C., Grabmaier, U., Theisen, D., von Ziegler, F., Leber, A. W., Becker, A., Sohn, H., Hoffmann, E., Mansmann, U., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.11.180 · Cited by 24
Tseng, C., Liao, W., Chang, C., Lee, C., Tseng, C., Hsu, Y., & Lin, J. (2016) · Pancreatology · doi:10.1016/j.pan.2016.10.003 · Cited by 24
“The SAVOR-TIMI 53 study and the EXAMINE study both failed to show an increased risk of pancreatic cancer among users of incretin-based drugs [12,13].”
BackgroundCombination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus
Moon, M. K., Hur, K. Y., Ko, S., Park, S.-O., Lee, B., Kim, J. H., Rhee, S. Y., Kim, H. J., Choi, K. M., & Kim, N. H. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.354 · Cited by 33
“The CV safety of DPP4i has been demonstrated through the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus– Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53), the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE), and the Trial Evaluat…”
MethodHuang, C., Wang, W., Sung, S., Chen, C., Lip, G. Y. H., Cheng, H., & Chiang, C. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13342 · Cited by 24
Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease
Jiménez, D. L., Cherney, D. Z. I., Bjornstad, P., Castilla‐Guerra, L., & Miramontes‐González, J. P. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00384.2017 · Cited by 27
“Studies were as follows: CARMELINA (60): Cardiovascular and Renal Microvascular Outcome Study with Linagliptin in Patients with Type 2 Diabetes Mellitus (NCT01897532); CAROLINA (41): Cardiovascular Outcome Study of Linagliptin vs. Glimepiride in Patients with Type 2 Diabetes (NCT01243424); EXAMINE (80): Examination of…”
BackgroundZhang, X., Shao, F., Zhu, L., Ze, Y., Zhu, D., & Bi, Y. (2018) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-018-0246-x · Cited by 26
Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy
Volpe, M., Societies, O. B. O. T. S., Battistoni, A., Gallo, G., Rubattu, S. D., & Tocci, G. (2018) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-018-0278-8 · Cited by 29
Advances in the management of diabetes: therapies for type 2 diabetes
Tsoutsouki, J., Wunna, W., Chowdhury, A., & Chowdhury, T. A. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-137404 · Cited by 31
Zhang, F., Xu, S., Tang, L., Pan, X., & Tong, N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00288 · Cited by 26
Origin and therapy for hypertriglyceridaemia in type 2 diabetes
Pang, J., Chan, D. C., & Watts, G. F. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i2.165 · Cited by 26
Barnett, A. H., Charbonnel, B. H., Moses, R. G., & Kalra, S. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1081589 · Cited by 26
Drugs for type 2 diabetes: role in the regulation of bone metabolism
Mannucci, E., & Dicembrini, I. (2015) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2015.12.2.130 · Cited by 29
Chen, H., Zhou, X., Chen, T., Liu, B., Jin, W., Gu, H., Hong, T., & Zhang, G. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0198-3 · Cited by 24
“Within the seven trials with incretin-matched placebos, four were recent large RCTs including SAVOR-TIMI 53 trial (NCT00790205) and EXAMINE trial (NCT00968708) [23, 26, 29, 30, 63].”
BackgroundPharmacological management of type 2 diabetes: what’s new in 2017?
Scheen, A. J. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1376652 · Cited by 27
“One intriguing result was the significant increase in the rate of hospitalization for HF in SAVOR-TIMI 53 with saxagliptin [41], an effect not retrieved at all with sitagliptin in TECOS [40] (only a nonsignificant trend was reported in EXAMINE with alogliptin) [39] (Table 1).”
BackgroundWhite, W. B., Heller, S. R., Cannon, C. P., Howitt, H., Khunti, K., & Bergenstal, R. M. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.02.023 · Cited by 23
Self-citationDiabetes and Vascular Disease: Is It All About Glycemia?
Vecchié, A., Montecucco, F., Carbone, F., Dallegri, F., & Bonaventura, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190830181944 · Cited by 24
Funamizu, T., Iwata, H., Nishida, Y., Miyosawa, K., Doi, S., Chikata, Y., Shitara, J., Endo, H., Wada, H., Naito, R., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-00996-8 · Cited by 27
Cardiovascular Risk Factors: It's Time to Focus on Variability!
Barnett, M. P., & Bangalore, S. (2020) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2020.9.2.255 · Cited by 25
Giorgino, F., Vora, J. P., Fenici, P., & Solini, A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14055 · Cited by 25
Davies, M. J., Bianchi, C., & Del Prato, S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154242 · Cited by 23
Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes
Martins, E. B., Lima, E. G., Pitta, F. G., Carvalho, L. N. S., de Queiroz, T. D., & Junior, C. V. S. (2020) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.66.9.1283 · Cited by 25
Recent advances in new-onset diabetes mellitus after kidney transplantation
Montada-Atin, T., & Prasad, G. V. R. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i5.541 · Cited by 24
Jones, L., & Jones, A. M. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1029 · Cited by 25
“[50] Furthermore, it has also been postulated that this class exerts cardiovascular protection through GLP-1 modulation in vivo, which has well established cardiovascular effects through coronary artery endothelial cell .”
BackgroundResultAntidiabetic treatment, stroke severity and outcome
Magkou, D., & Τζιόμαλος, Κ. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i2.84 · Cited by 24
Cardiovascular effects of anti-diabetes drugs
Younk, L. M., Lamos, E. M., & Davis, S. N. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1195368 · Cited by 24
“No difference between groups was found for the composite primary end point of cardiovascular death, MI, and stroke [58].”
BackgroundOmarigliptin for the treatment of type 2 diabetes mellitus
Evans, P. M. S., & Bain, S. C. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1218472 · Cited by 23
“There have now been three CVOTs of DPP-4 inhibitors (saxagliptin [33], alogliptin [34], and sitagliptin [35]), which confirmed their primary endpoint – demonstration of noninferiority for a composite cardiovascular (CV) endpoint versus placebo.”
BackgroundTreatment of Type 2 Diabetes: From “Guidelines” to “Position Statements” and Back
Mosenzon, O., Pollack, R. M., & Raz, I. (2016) · Diabetes Care · doi:10.2337/dcs15-3003 · Cited by 30
Clinical Approach to Diabetic Cardiomyopathy: A Review of Human Studies
Tarquini, R., Pala, L., Brancati, S., Vannini, G., Cosmo, S. D., Mazzoccoli, G., & Rotella, C. M. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170705111356 · Cited by 30
“To date, 3 DPP4 inhibitors (saxagliptin [107], alogliptin [108], and sitagliptin [109] and one GLP-1 agonist (lixisenatide [110], published data on cardiovascular outcomes.”
BackgroundThe Genetic Link Between Diabetes and Atherosclerosis
Ross, S. A., Gerstein, H. C., & Paré, G. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.01.016 · Cited by 24
Landgraf, R., Kellerer, M., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., et al. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-115964 · Cited by 24
Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus
Ikeda, M., & Shimazawa, R. (2019) · Journal of General and Family Medicine · doi:10.1002/jgf2.244 · Cited by 28
Darsalia, V., Johansen, O. E., Lietzau, G., Nyström, T., Klein, T., & Patrone, C. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00493 · Cited by 25
“Within the class of DPP-4i, four large CV outcome trials have been published till date for saxagliptin (75), sitagliptin (76), alogliptin (77), and linagliptin (32).”
BackgroundResultYamada, T., Iwasaki, K., Maedera, S., Ito, K., Takeshima, T., Noma, H., & Shojima, N. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1706043 · Cited by 23
New antidiabetic therapy and HFpEF: light at the end of tunnel?
Tadić, M., Sala, C., Saeed, S., Grassi, G. M., Mancia, G., Rottbauer, W., & Cuspidi, C. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10106-9 · Cited by 25
White, W. B., Jalil, F., Cushman, W. C., Bakris, G. L., Bergenstal, R., Heller, S. R., Liu, Y., Mehta, C., Zannad, F., & Cannon, C. P. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009114 · Cited by 22
Self-citationEffects of incretin-based therapy in patients with heart failure and myocardial infarction
Mikhail, N. E. (2014) · Endocrine · doi:10.1007/s12020-014-0175-4 · Cited by 24
Sportiello, L., Rafaniello, C., Scavone, C., Vitale, C., Rossi, F., & Capuano, A. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.10.002 · Cited by 27
DPP-4 inhibitors and risk of heart failure EXAMINEd
Standl, E., & Schnell, O. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60037-x · Cited by 22
Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective
Thompson, P. L., & Davis, T. M. E. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.10.008 · Cited by 26
Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip
Luconi, M., Cantini, G., Ceriello, A., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.126 · Cited by 24
Inagaki, N., Yang, W., Watada, H., Ji, L., Schnaidt, S., Pfarr, E., Okamura, T., Johansen, O. E., George, J. T., von Eynatten, M., et al. (2019) · Diabetology International · doi:10.1007/s13340-019-00412-x · Cited by 23
Role of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction: A Review Article
Mgbemena, O. N., Zhang, Y., & Velarde, G. (2021) · Cureus · doi:10.7759/cureus.19398 · Cited by 30
“These neutral classes of medications include DPP-4 inhibitors [43,44]; insulin (glargine) [45,46]; alpha-glucosidase inhibitors [47-49]; glinides [50]; D2-dopamine agonists [46]; GLP-1 agonist [51-53]; and sulfonylurea [54].”
BackgroundChi, G., Lee, J., Kazmi, S. H. A., Fitzgerald, C., Montazerin, S. M., Kalaycı, A., Korjian, S., Heise, M. A., Deckelbaum, L. I., Libby, P., et al. (2022) · Clinical Cardiology · doi:10.1002/clc.23773 · Cited by 27
Richardson, T. L., Halvorson, A. E., Hackstadt, A. J., Hung, A. M., Greevy, R. A., Grijalva, C. G., Elasy, T. A., & Roumie, C. L. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2751 · Cited by 24
Kannan, S., Pantalone, K. M., Matsuda, S., Wells, B. J., Karafa, M., & Zimmerman, R. S. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12301 · Cited by 25
“The recently concluded SAVOR TIMI and EXAMINE trials did not identify a cardiovascular risk reduction with saxagliptin or alogliptin, respectively.(13,14)”
MethodResultFujiwara, T., Yoshida, M., Yamada, H., Tsukui, T., Nakamura, T., Sakakura, K., Wada, H., Arao, K., Katayama, T., Funayama, H., et al. (2014) · Heart and Vessels · doi:10.1007/s00380-014-0502-y · Cited by 23
“Furthermore, recent studies which evaluated effect of dipeptidyl peptidase-4 inhibitors for cardiovascular events reported that reduced HbA1c is not related to the prevention of cardiovascular events [26, 27].”
BackgroundAlogliptin: Safety, Efficacy, and Clinical Implications
Marino, A. B., & Cole, S. W. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014522063 · Cited by 23
“EXAMINE concludes that among patients with type 2 diabetes who have had a recent ACS, the rates of major adverse CV events are not increased with alogliptin when compared to placebo.(16)”
BackgroundGliptins – do they increase cardiovascular risk or benefit?
Doggrell, S. A., & Dimmitt, S. B. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.904284 · Cited by 22
“However, hospitalisation for heart failure was not an end point in EXAMINE, and [13] thus we do not know whether alogliptin has an effect on hospitalisations for heart failure.”
BackgroundMethodInfluentialCardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.
Kankanala, S., Syed, R. M., Gong, Q., Ren, B., Rao, X., & Zhong, J. (2016) · PubMed Central · Cited by 23
White, W. B., Wilson, C., Bakris, G. L., Bergenstal, R. M., Cannon, C. P., Cushman, W. C., Heller, S. K., Mehta, C. R., Nissen, S. E., Zannad, F. M., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07797 · Cited by 23
“ACSs included diagnoses of acute myocardial infarction (MI) or hospitalization with unstable angina as previously defined.(10,11) Major exclusion criteria were a diagnosis of type 1 diabetes mellitus, unstable cardiac disorders such as New York Heart Association class 4 heart failure (HF), refractory angina, uncontrol…”
MethodSelf-citationRahelić, D., Javor, E., Lucijanić, T., & Skelin, M. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1226514 · Cited by 26
Veeranki, S., & Tyagi, S. C. (2017) · Physiological Reports · doi:10.14814/phy2.13298 · Cited by 23
“Currently, the significance of such variations is unknown, but SDF-1/CXCR4 axis has a dual role in the myocardial recovery (Liehn et al. 2011; Scirica et al. 2013; White et al. 2013; Weir et al. 2014; Chung et al. 2015; Zhong and Rajagopalan 2015).”
BackgroundUmpierrez, G. E., Bailey, T. S., Carcia, D., Shaefer, C. F., Shubrook, J. H., & SKOLNIK, N. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12576 · Cited by 25
Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure
Verbrugge, F. H. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0340-1 · Cited by 25
Suda, M., Shimizu, I., Yoshida, Y., Hayashi, Y., Ikegami, R., Katsuumi, G., Wakasugi, T., Yoshida, Y., Okuda, S., Soga, T., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182422 · Cited by 22
dʼEmden, M. C., Amerena, J. V., Deed, G., Pollock, C. A., & Cooper, M. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.11.023 · Cited by 27
Chiang, C., Lin, S.-Y., Lin, T., Wang, T., Yeh, H., Chen, J., Tsai, C., Hung, Y.-J., Li, Y., Liu, P., et al. (2018) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2018.01.001 · Cited by 22
“2% of patients had a history of stroke.(23) The overall efficacy in the 3-point MACE showed no difference with the use of alogliptin”
BackgroundMethodResultInfluentialMenon, V., Lincoff, A. M., Nicholls, S. J., Jasper, S. E., Wolski, K., McGuire, D. K., Mehta, C. R., Rosenstock, J., Lopez, C. M., MARCINAK, J. F., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0755 · Cited by 24
Self-citationNova abordagem para o tratamento da diabetes: da glicemia à doença cardiovascular
Aguíar, C., Duarte, R., & Carvalho, D. M. (2019) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2018.03.013 · Cited by 48
Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell
Zhang, H., Sun, D., Wang, G., Cui, S., Field, R. A., Li, J. X., & Zang, Y. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.02.065 · Cited by 24
Li, G., Crowley, M. J., Tang, H., Yang, J. Y., Sandler, R. S., & Wang, T. (2019) · Diabetes Care · doi:10.2337/dc18-1578 · Cited by 22
Predictors of heart failure development in type 2 diabetes: a practical approach
Verma, S., Sharma, A., Kanumilli, N., & Butler, J. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000647 · Cited by 26
Martínez, J. J. G., Malkin, S. J. P., Martín, V., Hallén, N., & Hunt, B. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1681436 · Cited by 24
Oral antidiabetes agents for the management of inpatient hyperglycaemia: so far, yet so close
Koufakis, T., Mustafa, O. G., Zebekakis, P. E., & Kotsa, K. (2020) · Diabetic Medicine · doi:10.1111/dme.14329 · Cited by 24
Antidiabetic drugs and blood pressure changes
Ilias, Ι., Thomopoulos, C., Michalopoulou, H., Bazoukis, G., Tsioufis, C. P., & Makris, T. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105108 · Cited by 28
Guthoff, M., Vosseler, D., Langanke, J., Nadalin, S., Königsrainer, A., Häring, H., Fritsche, A., & Heyne, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134971 · Cited by 23
Dermatitis due to Olindias sambaquiensis: a case report.
Kokelj, F., Mianzán, H., Avian, M., & Burnett, J. W. (1993) · PubMed · Cited by 25
Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium
Sager, P. T., Seltzer, J. H., Turner, J. R., Anderson, J. L., Hiatt, W. R., Kowey, P. R., Prochaska, J. J., Stockbridge, N., & White, W. B. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.01.007 · Cited by 24
“However, to whatever extent one is concerned about the final confidence limits, how and whether to review interim results requires substantial thought and preparation to preserve the integrity of the trial.(12) Alternatives to dedicated CV outcome studies.”
BackgroundSelf-citationCardiovascular Safety Evaluation in the Development of New Drugs for Diabetes Mellitus
Menon, V., & Lincoff, A. M. (2014) · Circulation · doi:10.1161/circulationaha.113.008221 · Cited by 21
Practical combination therapy based on pathophysiology of type 2 diabetes
LEVIN, P. A. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s109216 · Cited by 22
Singh, A. K., & Singh, R. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1287562 · Cited by 21
Chai, S., Yu, S., Yang, Z., Wu, S., Gao, L., Wang, H., Zhang, Y., Zhan, S., Ji, L., & Sun, F. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000728 · Cited by 22
Qin, Y., Yan, G., Qiao, Y., Wang, D., Luo, E., Hou, J., & Tang, C. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01394-4 · Cited by 22
Gouda, P., Zheng, S., Peters, T. M., Fudim, M., Randhawa, V. K., Ezekowitz, J. A., Mavrakanas, T. A., Giannetti, N., Tsoukas, M. A., Lópes, R. D., et al. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00527-w · Cited by 28
“Subgroup analyses of RCTs of dipeptidyl-peptidase 4-inhibitors (DPP-4i) suggest a greater clinical benefit in patients with diabetes duration of < 10 years [13], on baseline biguanide therapy [13] or on baseline thiazolidinediones therapy [14].”
BackgroundLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1193-3793 · Cited by 33
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
Conde, A. C., Martín, D. M., Ruíz, R. C., Olmo, M. R. F., Ariño, C. M., Gómez‐Doblas, J. J., Górriz, J. L., Mazón‐Ramos, P., García–Moll, X., Soler, M. J., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123925 · Cited by 23
“The FDA published a communication warning about the association of HF with the use of saxagliptin and alogliptin [67], despite the fact that the EXAMINE [68] study did not find a significant difference in the increase in HF in the alogliptin group, but it was observed in the SAVOR-TIMI 53 [69] study with saxagliptin.”
ResultEmerging role of antidiabetic drugs in cardiorenal protection
Fu, W.-J., Huo, J., Mao, Z., Pan, S.-K., Liu, D., Liu, Z., Wu, P., & Gao, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349069 · Cited by 24
DPP-IV as a potential candidate in anti-obesity and obesity-related diseases treatment
Guo, X., Feng, H., Cai, L., Zheng, J., & Li, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117464 · Cited by 22
Fiorentino, T. V., Owston, M. A., ABRAHAMIAN, G. A., Rosa, S. L., Marando, A., Perego, C., Cairano, E. S. D., Finzi, G., Capella, C., Sessa, F., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.09.009 · Cited by 21
Carotid atherosclerosis progression and cerebrovascular events in patients with diabetes
Vouillarmet, J., Helfre, M., Maucort‐Boulch, D., Riche, B., Thivolet, C. H., & Grangé, C. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.01.022 · Cited by 22
“This rate of cerebrovascular events is low but in accordance to those found in recent clinical trials assessing vascular events in diabetes, with a rate of events ranging from 0,1 to 0,8% per year (Gerstein et al., 2011; White et al., 2013; Scirica et al., 2013).”
Sadhu, A., Schwartz, S. S., & Herman, M. E. (2015) · Endocrine Practice · doi:10.4158/ep14569.ra · Cited by 23
“Two recent large-scale studies were included in this analysis, each of which reported low rates that were similar in the drug and placebo groups (46,47).”
Novel antidiabetic drugs and cardiovascular risk: Primum non nocere
Bonadonna, R. C., Borghi, C., Consoli, A., & Volpe, M. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.05.007 · Cited by 24
“Similarly, there was no difference in total CV deaths [27].”
BackgroundSGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan
Ito, H., Shinozaki, M., Nishio, S., & Abe, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1232395 · Cited by 27
Re, V. L., Carbonari, D. M., Saine, M. E., Newcomb, C. W., Roy, J. A., Liu, Q., Wu, Q., Cardillo, S., Haynes, K., Kimmel, S. E., et al. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000400 · Cited by 25
Metadata
- Authors
- White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., Cushman, W. C., & Zannad, F.
- Affiliations
- University of Connecticut (US)
- Brigham and Women's Hospital (US)
- University of Sheffield (GB)
- Cleveland Clinic (US)
- Park Nicollet Health Services (US)
- University of Chicago (US)
- Takeda (United States) (US)
- Harvard University (US)
- Memphis VA Medical Center (US)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1327-1335
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127854619
- Cited by
- 2,502
- References
- 23
- Citations by year
- 2026: 43 · 2025: 60 · 2024: 79 · 2023: 107 · 2022: 124 · 2021: 161 · 2020: 225 · 2019: 243 · 2018: 288 · 2017: 279 · 2016: 329 · 2015: 260 · 2014: 248 · 2013: 44
- FWCI
- 231.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0611-10248)
- National Institutes of Health (UL1TR000041)
- Japan Society for the Promotion of Science (24591075)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- alogliptin, DPP-4 inhibitors, type 2 diabetes, acute coronary syndrome, major adverse cardiovascular events, cardiovascular safety, non-inferiority, HbA1c, acute myocardial infarction, unstable angina, hypoglycemia
- MeSH terms
- Aged, Angina, Unstable, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Piperidines, Uracil, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.